Guest guest Posted January 21, 2008 Report Share Posted January 21, 2008 Reduced-Intensity Regimens in Allogeneic Stem-Cell Transplantation for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia http://asheducationbook.hematologylibrary.org/cgi/reprint/2006/1/390.pdf Summary: Summary: The current data collectively suggest that addition of anti-CD20 monoclonal antibodies significantly improves the outcome of autologous SCT in patients with NHL who have chemosensitive disease (Table 3). It is recommended for patients with DLCL or Follicular Lymphoma undergoing their first relapse and MCL during first remission, but not in patients with CLL. (My note: But not necessarily the standard of care for any histology) A significant Graft versus Lymphoma effect can be achieved clinically through the use of nonmyeloablative transplantation in patients with chemosensitive advanced disease. Yet the applicability of nonmyeloablative SCT appears dependent on disease histologic type, individual patient, and disease characteristics. The current data suggest an increased risk of relapse with the use of alemtuzumab. Randomized studies may allow the comparison of various nonmyeloablative transplantation strategies. High-dose conditioning regimens should be considered for patients with chemorefractory (resistant) disease who are young and have a good performance status. The field offers significant opportunity for clinical research, and we strongly encourage participation in clinical trials whenever possible. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.